Alogliptin: No link with increased heart failure events
KEY POINT
The use of alogliptin (Nesina—Takeda) in patients with type 2 diabetes and a recent acute coronary syndrome (ACS) event was not associated with an increased risk of heart failure–related outcomes, according to new analysis of previous trial data.
SOURCES
Zannad F et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicenter, randomized, double-blind trial. Lancet. 2015;[Epub ahead of print].
